Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Unaudited Results Announcement)
Reporting Period: Third Quarter (Q3) and Nine Months ended 30 September 2009
Key Strategic Focus: Diversification away from "white pill/western markets" toward Emerging Markets, Japan, and Consumer Healthcare. The company is executing a restructuring program targeting £1.7 billion in annual savings.
Key Financial Metrics
| Metric | Q3 2009 (£m) | Q3 2008 (£m) | CER Growth % | 9 Months 2009 (£m) | 9 Months 2008 (£m) | CER Growth % |
|---|---|---|---|---|---|---|
| Turnover | 6,758 | 5,882 | +3% | 20,274 | 17,442 | -1% |
| Operating Profit (Pre-Restructuring) | 2,223 | 1,979 | -3% | 6,580 | 6,153 | -13% |
| Operating Profit (Total) | 2,071 | 1,657 | +7% | 5,978 | 5,559 | -14% |
| Profit After Tax (Shareholders) | 1,444 | 1,287 | - | 4,349 | 4,085 | - |
| EPS (Pre-Restructuring) | 28.5p | 25.2p | -3% | 85.8p | 78.0p | -12% |
| EPS (Total) | 26.3p | 20.1p | +11% | 77.0p | 69.2p | -12% |
| Net Cash Inflow (Operating) | 2,081 | - | +10% (Sterling) | 5,580 | 5,067 | +10% (Sterling) |
| Net Debt | 10.2 billion | - | - | 10.2 billion | 10.2 billion | - |
Note: CER = Constant Exchange Rate. EPS figures are per share.
Material Changes vs. Prior Period
- Return to Sales Growth: Q3 turnover grew 3% (CER) and 15% (Sterling), reversing the decline seen in the nine-month period (-1% CER). This was driven by Emerging Markets (+25%), Japan (+19%), and Consumer Healthcare (+8%).
- US Market Decline: US pharmaceutical sales fell 12% in Q3 and 16% for the nine months, primarily due to generic competition for CNS products (Imigran, Lamictal, Requip) and pricing pressures.
- Acquisition Impact: The acquisition of Stiefel Laboratories (July 2009) contributed £111 million to Q3 pharmaceutical turnover. Stiefel is expected to be integrated into regional segments starting Q1 2010.
- Cost Structure: Cost of sales increased to 25.6% of turnover in Q3 (from 24.8% in Q3 2008) due to generic competition. SG&A costs rose to 30.5% (from 28.3%) reflecting investment in growth markets and the Stiefel consolidation.
- Restructuring Charges: Q3 included £152 million in restructuring charges (down from £322 million in Q3 2008). Cumulative annualized savings from the program reached £1 billion.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Q4 Expectations: Management expects further improvement in Q4 2009, including significant sales from influenza products (Pandemrix).
- Dividend: A third interim dividend of 15p per share was declared, a 7% increase from the prior year.
- Cost Targets: The company expects full-year R&D costs to be broadly in line with 2008 (14.4% of sales) and SG&A (excluding legal) to be around 29% of turnover.
- Pipeline Momentum: 30 assets in late-stage development. Recent approvals include Cervarix (USA/Japan), Votrient, and Arzerra. Pandemrix (H1N1) was approved in Europe.
Risks and Contingencies
- Legal Proceedings: Aggregate provision for legal disputes is £1.7 billion. Notable developments include an adverse $2.5 million jury verdict in a Paxil birth defect trial (appeal planned) and a favorable ruling in Alabama regarding Medicaid fraud allegations.
- Patent Litigation: Novartis has sued GSK in Belgium and the UK regarding vaccine manufacturing patents. GSK has filed revocation actions.
- Generic Competition: Continued erosion of US sales due to generic entry for key products like Valtrex (expected in 2010) and CNS drugs.
- Pension Deficit: The net deficit on pension plans increased to £2.0 billion (from £1.7 billion) due to changes in inflation and discount rate assumptions.
Investor Verification Checklist
- US Sales Trajectory: Verify the extent of generic erosion on key CNS products and the timeline for Valtrex patent expiry impact in 2010.
- Stiefel Integration: Monitor the realization of the projected $240 million annual cost synergies and the integration of Stiefel into regional reporting in 2010.
- Legal Provisions: Track the outcome of the Paxil appeal and the Novartis patent revocation proceedings, as these could materially impact the £1.7 billion legal provision.
- Emerging Markets Growth: Confirm if the 25% growth in Emerging Markets is sustainable or driven by one-off tender wins (e.g., Synflorix in Brazil).
- Dividend Sustainability: Assess cash flow generation against the increased dividend payout and capital expenditure requirements for the restructuring program.